The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Targeting the EGFR signaling pathway in cancer therapy
Open accessAbstract
INTRODUCTION: Cancer is a devastating disease; however, several therapeutic advances have recently been made, wherein EGFR and its family members have emerged as useful biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF, which further induces tyrosine phosphorylation and receptor dimerization with other family members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such as monoclonal antibodies and tyrosine kinase inhibitors have been developed, which has enabled clinicians to identify and treat specific patient cohorts. AREAS COVERED: This review covers the basic mechanism of EGFR activation and the role of EGFR signaling in cancer progression. Furthermore, current developments made toward targeting the EGFR signaling pathway for the treatment of epithelial cancers and a summary of the various anti-EGFR therapeutic agents that are currently in use are also presented in this review. EXPERT OPINION: EGFR signaling is a part of a complex network that has been the target of effective cancer therapies. However, a further understanding of the system is required to develop an effective anticancer regimen. A combination therapy that comprises an anti-EGFR and a chemotherapeutic/chemopreventive agent will exhibit a multi-pronged approach that can be developed into a highly attractive and specific molecular oriented remedy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
El-Rayes, B. F., Ali, S. S., Ali, I. F., Philip, P. A., Abbruzzese, J. L., & Sarkar, F. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2333 · Cited by 123
RetractedGadgeel, S. M., Ali, S. S., Philip, P. A., Wozniak, A. J., & Sarkar, F. H. (2009) · Cancer · doi:10.1002/cncr.24250 · Cited by 79
RetractedLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 18×
“ErbB family members can be activated by 13 known ligands, which include EGF, transforming growth factor alpha (TGF-a), amphiregulin (AR), betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPR), epigen (EPG) and neuregulins 1 -- 6 (NRG) [10,11].”
BackgroundInfluentialGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“A randomized study in patients having advanced NSCLC and who had failed standard cytotoxic chemotherapy showed improved clinical symptoms and a better survival rate with erlotinib [84,86,87].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 1×
“Erlotinib, when combined with carboplatin/gemcitabine or cisplatin/paclitaxel in two separate randomized Phase III studies did not produce a survival advantage over chemotherapy alone [89-91].”
BackgroundCrystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Nuclear localization of EGF receptor and its potential new role as a transcription factor
Lin, S.-Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-802 · Cited by 1,064
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80231-2 · Cited by 1,001
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 881
γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase
Ni, C.-Y., Murphy, M. P., Golde, T. E., & Carpenter, G. (2001) · Science · doi:10.1126/science.1065412 · Cited by 856
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Transforming Growth Factor-α: a More Potent Angiogenic Mediator than Epidermal Growth Factor
Schreiber, A. B., Winkler, M. E., & Derynck, R. (1986) · Science · doi:10.1126/science.2422759 · Cited by 838
The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy
Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 827
Wells, A. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00015-1 · Cited by 817
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 647
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 597
Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway
Lo, H.-W., Hsu, S.-C., Ali-Seyed, M., Gunduz, M., Xia, W., Wei, Y., Bartholomeusz, G., Shih, J.-Y., & Hung, M.-C. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.007 · Cited by 544
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 532
Goldman, C. K., Kim, J., Wong, W. L., King, V, Brock, T., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R., & Rodemann, H. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506591200 · Cited by 529
Douillard, J.-Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Liao, M.-L., Bischoff, H., Reck, M., Sellers, M. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3030 · Cited by 492 · cited 2×
“Recent studies evaluating EGFR TKIs in patients with these activating EGFR gene mutations demonstrated a consistent improvement in progression-free survival, but none of these trials have demonstrated an improvement in overall survival [126-128].”
BackgroundDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Cho, H.-S., & Leahy, D. J. (2002) · Science · doi:10.1126/science.1074611 · Cited by 447
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 418
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
Gefitinib — a novel targeted approach to treating cancer
Herbst, R. S., Fukuoka, M., & Baselga, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1506 · Cited by 401
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Lee, J. C., Vivanco, I., Beroukhim, R., Huang, J. H. Y., Feng, W. L., DeBiasi, R. M., Yoshimoto, K., King, J. C., Nghiemphu, P., Yuza, Y., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030485 · Cited by 367
The role of the EGFR signaling in tumor microenvironment
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D., Pinto, A., & Normanno, N. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21260 · Cited by 359
The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn, J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080003 · Cited by 330
Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P., & Awada, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1443 · Cited by 324
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C. T., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080083 · Cited by 323
Signaling through the epidermal growth factor receptor during the development of malignancy
Grandis, J. R., & Sok, J. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.01.002 · Cited by 320
Batra, S. K., Castelino‐Prabhu, S., Wikstrand, C. J., Zhu, X., Humphrey, P. A., Friedman, H. S., & Bigner, D. D. (1995) · PubMed · Cited by 312
Self-citationBinding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2
Wang, S.-C., Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Lee, D.-F., Bartholomeusz, G., Ou-Yang, F., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.012 · Cited by 305
Maity, A. M., Pore, N., Lee, J. S. H., Solomon, D., & O’Rourke, D. M. (2000) · PubMed · Cited by 302
平田, 晃. (2004) · Medical Entomology and Zoology · Cited by 298
Dawson, J. P., Berger, M. B., Lin, C.-C., Schlessinger, J., Lemmon, M. A., & Ferguson, K. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7734-7742.2005 · Cited by 297
Novel Prognostic Value of Nuclear Epidermal Growth Factor Receptor in Breast Cancer
Lo, H.-W., Xia, W., Wei, Y., Ali-Seyed, M., Huang, S.-F., & Hung, M.-C. (2005) · Cancer Research · doi:10.1158/0008-5472.338.65.1 · Cited by 290
van Krieken, J. H. J. M., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F. T., Quirke, P., Fléjou, J. F., Plato Hansen, T., de Hertogh, G., et al. (2008) · Virchows Archiv · doi:10.1007/s00428-008-0665-y · Cited by 289
Waterman, H., Katz, M., Rubin, C., Shtiegman, K., Lavi, S., Elson, A., Jovin, T., & Yarden, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/21.3.303 · Cited by 286
The emergence of clathrin-independent pinocytic pathways
Lamaze, C., & Schmid, S. L. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80015-8 · Cited by 283
Kimura, H., Sakai, K., Arao, T., Shimoyama, T., Tamura, T., & Nishio, K. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00510.x · Cited by 277
EGFR Targeting of Solid Tumors
Rocha-Lima, C. M., Soares, H. P., Raez, L. E., & Singal, R. (2007) · Cancer Control · doi:10.1177/107327480701400313 · Cited by 274
Psyrri, A., Yu, Z., Weinberger, P. M., Sasaki, C., Haffty, B., Camp, R., Rimm, D., & Burtness, B. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0420 · Cited by 269
Agulnik, M., Cohen, E. W. E., Cohen, R. B., Chen, E. X., Vokes, E. E., Hotte, S. J., Winquist, E., Laurie, S., Hayes, D. N., Dancey, J. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8612 · Cited by 263
Skin toxicities associated with epidermal growth factor receptor inhibitors
Li, T., & Perez-Soler, R. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0114-0 · Cited by 261
Hirata, A., Ogawa, S.-I., Kometani, T., Kuwano, T., Naito, S., Kuwano, M., & Ono, M. (2002) · PubMed · Cited by 256
Sunada, H., Magun, B. E., Mendelsohn, J., & MacLeod, C. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.3825 · Cited by 253
Ebner, R., & Derynck, R. (1991) · Cell Regulation · doi:10.1091/mbc.2.8.599 · Cited by 248
Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1
Lo, H., Ali‐Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S., & Hung, M. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20876 · Cited by 240
Lo, H.-W., Hsu, S.-C., & Hung, M.-C. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9011-0 · Cited by 237
Bancroft, C. C., Chen, Z., Yeh, J., Sunwoo, J. B., Yeh, N. T., Jackson, S., Jackson, C., & Van Waes, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10398 · Cited by 230
Hu, J. C., Sadeghi, P., Pinter-Brown, L. C., Yashar, S., & Chiu, M. W. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.09.005 · Cited by 229
Offterdinger, M., Schöfer, C., Weipoltshammer, K., & Grunt, T. W. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200109033 · Cited by 208
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
Roepstorff, K., Grøvdal, L., Grandal, M., Lerdrup, M., & van Deurs, B. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0401-3 · Cited by 202
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
Hecht, J. R., Patnaik, A., Berlin, J., Venook, A., Malik, I., Tchekmedyian, S., Navale, L., Amado, R. G., & Meropol, N. J. (2007) · Cancer · doi:10.1002/cncr.22915 · Cited by 202
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
Ciardiello, F. (2000) · Drugs · doi:10.2165/00003495-200060001-00003 · Cited by 194
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M., & Leahy, D. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507591102 · Cited by 192
Co‐regulation of B‐Myb expression by E2F1 and EGF receptor
Hanada, N., Lo, H., Day, C., Pan, Y., Nakajima, Y., & Hung, M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20147 · Cited by 188
EGF receptor ubiquitination is not necessary for its internalization
Huang, F., Goh, L. K., & Sorkin, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707416104 · Cited by 187
Grøvdal, L. M., Stang, E., Sorkin, A., & Madshus, I. H. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.003 · Cited by 182
Smaill, J. B., Palmer, B. D., Rewcastle, G. W., Denny, W. A., McNamara, D. J., Dobrusin, E. M., Bridges, A. J., Zhou, H., Showalter, H. D. H., Winters, R. T., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806603 · Cited by 177
Tyrosine kinase inhibitors—ZD1839 (Iressa)
Arteaga, C. L., & Johnson, D. H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00012 · Cited by 172
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation
Thomas, S. M., & Grandis, J. R. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.10.003 · Cited by 171
Madshus, I. H., & Stang, E. (2009) · Journal of Cell Science · doi:10.1242/jcs.050260 · Cited by 167
Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, A. E., Barker, A. J., Davies, D. H., Brown, D. S., Green, L. R., Cartlidge, S. A., & Woodburn, J. R. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803785 · Cited by 166
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., & Burstein, H. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn759 · Cited by 164
MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells
Chaturvedi, P., Singh, A. P., Chakraborty, S., Chauhan, S. C., Bafna, S., Meza, J. L., Singh, P. K., Hollingsworth, M. A., Mehta, P. P., & Batra, S. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6041 · Cited by 163
Self-citationBareschino, M. A., Schettino, C., Troiani, T., Martinelli, E., Morgillo, F., & Ciardiello, F. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm222 · Cited by 162
Anticancer therapy targeting the erbB family of receptor tyrosine kinases
Slichenmyer, W. J., & Fry, D. W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90284-2 · Cited by 158
Normanno, N., Maiello, M. R., & Luca, A. D. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10194 · Cited by 157
Siwak, D. R., Carey, M. S., Hennessy, B. T., Nguyen, C. T. Y., Murray, M. M., Nolden, L. K., & Mills, G. B. (2009) · Journal of Oncology · doi:10.1155/2010/568938 · Cited by 156
Lev‐Ari, S., Starr, A., Vexler, A. M., Karaush, V., Loew, V., Greif, J., Fenig, E., Aderka, D., & Ben‐Yosef, R. (2006) · PubMed · Cited by 151
Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer
Cohen, R. B. (2003) · Clinical Colorectal Cancer · doi:10.3816/ccc.2003.n.006 · Cited by 151
Pore, N., Liu, S., Haas-Kogan, D. A., O’Rourke, D. M., & Maity, A. M. (2003) · PubMed · Cited by 151
Xia, W., Wei, Y., Du, Y., Liu, J., Chang, B., Yu, Y., Huo, L., Miller, S. A., & Hung, M. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20504 · Cited by 151
Jiang, X., & Sorkin, A. D. (2003) · Traffic · doi:10.1034/j.1600-0854.2003.t01-1-00109.x · Cited by 143
The EGF Receptor System as a Target for Antitumor Therapy
Ennis, B. W., Lippman, M. E., & Dickson, R. B. (1991) · Cancer Investigation · doi:10.3109/07357909109018953 · Cited by 143
Xie, Y., & Hung, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2368 · Cited by 134
Localization of epidermal growth factor receptor in hepatocyte nuclei
Marti, U., Burwen, S. J., Wells, A. H., Barker, M. E., Huling, S. L., Feren, A. M., & Jones, A. L. (1991) · Hepatology · doi:10.1002/hep.1840130104 · Cited by 129
Lynch, D. H., & Yang, X. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31522 · Cited by 128
Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 127
Hwang, Y. P., Yun, H. J., Choi, J. H., Han, E. H., Kim, H. G., Song, G., Kwon, K., Jeong, T. C., & Jeong, H. G. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201000292 · Cited by 121
Epidermal growth factor receptor tyrosine kinase inhibitors
Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601873 · Cited by 118
RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus
Huo, L., Wang, Y., Xia, W., Hsu, S.-C., Lai, C., Li, L., Chang, W., Wang, Y., Hsu, M., Yu, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000743107 · Cited by 118
Rao, G., Murray, S., & Ethier, S. P. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)01358-4 · Cited by 117
Nelson, J. M., & Fry, D. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008786200 · Cited by 108
Barrière, H., Nemes, C., Du, K., & Lukács, G. L. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-07-0678 · Cited by 103
Advances in Target Therapy for Lung Cancer
Mitsudomi, T. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp174 · Cited by 95
Perez-Soler, R. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.010 · Cited by 91
Nesterov, A., Wiley, H. S., & Gill, G. N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8719 · Cited by 89
Sini, P., Wyder, L., Schnell, C., O’Reilly, T., Littlewood, A., Brandt, R., Hynes, N. E., & Wood, J. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1954 · Cited by 87
Radiosensitization by Pan ErbB Inhibitor CI-1033 in Vitro and in Vivo
Nyati, M. K., Maheshwari, D., Hanasoge, S., Sreekumar, A., Rynkiewicz, S. D., Chinnaiyan, A. M., Leopold, W. R., Ethier, S. P., & Lawrence, T. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1041-03 · Cited by 86
Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1149-0 · Cited by 85
MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells
Ponnusamy, M. P., Singh, A. P., Jain, M., Chakraborty, S., Moniaux, N., & Batra, S. K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604517 · Cited by 83
Self-citationEpidermal Growth Factor ReceptorMutation Testing in the Care of Lung Cancer Patients
Sequist, L. V. D., Joshi, V. A., Janne, P. A., Bell, D. W., Fidias, P. M., Lindeman, N. I., Louis, D. N., Lee, J. C., Mark, E. J., Longtine, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0099 · Cited by 81
Role of the ErbB-4 Carboxyl Terminus in γ-Secretase Cleavage
Ni, C.-Y., Yuan, H., & Carpenter, G. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210504200 · Cited by 77
Dw, F. (2000) · PubMed · Cited by 72
Allen, L. F., Lenehan, P. F., Eiseman, I. A., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34049 · Cited by 71
Rizvi, N. A., Rusch, V. W., Pao, W. J., Chaft, J. E., Ladanyi, M., Miller, V. A., Krug, L. M., Azzoli, C. G., Bains, M. S., Downey, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2102 · Cited by 70
Decker, S. J. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90853-f · Cited by 64
Giaccone, G., González-Larriba, J. L., van Oosterom, A. T., Alfonso, R., Smit, E. F., Martens, M., Peters, G. J., van der Vijgh, W. J. F., Smith, R. P., Averbuch, S. D., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh188 · Cited by 59
Gieseg, M. A., de Bock, C. E., Ferguson, L. R., & Denny, W. A. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200109000-00007 · Cited by 53
Epithelial growth factor receptor interacting agents
Baselga, J. M., & Albanell, J. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00055-2 · Cited by 51
K-ras as a Target for Lung Cancer Therapy
Adjei, A. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174dbf9 · Cited by 45
Metastatic Colorectal Cancer: Systemic Treatment in the New Millennium
Coutinho, A. K., & Lima, C. M. S. R. (2003) · Cancer Control · doi:10.1177/107327480301000306 · Cited by 37
Ako, E., Yamashita, Y., Ohira, M., Yamazaki, M., Hori, T., Kubo, N., Sawada, T., & Hirakawa, K. (2007) · Oncology Reports · doi:10.3892/or.17.4.887 · Cited by 29
Are current drug development programmes realising the full potential of new agents? The scenario
Johnston, S. R. D. (2009) · Breast Cancer Research · doi:10.1186/bcr2440 · Cited by 4
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 591
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Thiazole-containing compounds as therapeutic targets for cancer therapy
Sharma, P. C., Bansal, K. K., Sharma, A., Sharma, D., & Deep, A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.112016 · Cited by 382
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Metadata
- Authors
- Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 16
- Issue
- 1
- Pages
- 15-31
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2003867647
- Cited by
- 913
- References
- 135
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.